Charles River Laboratories International (NYSE:CRL) EVP Shannon Parisotto Sells 5,046 Shares

Charles River Laboratories International, Inc. (NYSE:CRL) EVP Shannon Parisotto sold 5,046 shares of the company’s stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $263.00, for a total transaction of $1,327,098.00. Following the transaction, the executive vice president owned 4,807 shares in the company, valued at approximately $1,264,241. This trade represents a 51.21% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Charles River Laboratories International Stock Performance

Shares of Charles River Laboratories International stock opened at $265.73 on Friday. The company has a 50 day moving average price of $213.14 and a 200 day moving average price of $188.71. The firm has a market capitalization of $12.80 billion, a P/E ratio of -54.79, a PEG ratio of 2.86 and a beta of 1.38. The company has a quick ratio of 1.03, a current ratio of 1.35 and a debt-to-equity ratio of 0.92. Charles River Laboratories International, Inc. has a 52 week low of $144.26 and a 52 week high of $268.00.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share for the quarter, topping the consensus estimate of $2.77 by $0.25. Charles River Laboratories International had a negative net margin of 5.96% and a positive return on equity of 15.75%. The company had revenue of $1 billion for the quarter, compared to the consensus estimate of $980.53 million. During the same quarter in the previous year, the firm earned $3.12 EPS. Charles River Laboratories International’s revenue was down 2.7% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. Sell-side analysts expect that Charles River Laboratories International, Inc. will post 11.23 EPS for the current year.

Institutional Investors Weigh In On Charles River Laboratories International

Several hedge funds have recently bought and sold shares of CRL. Jones Financial Companies Lllp lifted its stake in shares of Charles River Laboratories International by 167.6% in the 1st quarter. Jones Financial Companies Lllp now owns 1,715 shares of the medical research company’s stock valued at $253,000 after purchasing an additional 1,074 shares during the period. Empowered Funds LLC purchased a new position in Charles River Laboratories International in the first quarter valued at $418,000. American Century Companies Inc. increased its holdings in Charles River Laboratories International by 41.9% in the second quarter. American Century Companies Inc. now owns 5,469 shares of the medical research company’s stock valued at $830,000 after buying an additional 1,616 shares in the last quarter. Brown Advisory Inc. raised its position in shares of Charles River Laboratories International by 5.1% in the second quarter. Brown Advisory Inc. now owns 2,333 shares of the medical research company’s stock worth $354,000 after acquiring an additional 114 shares during the period. Finally, California Public Employees Retirement System boosted its stake in shares of Charles River Laboratories International by 3.9% during the 2nd quarter. California Public Employees Retirement System now owns 84,605 shares of the medical research company’s stock worth $12,837,000 after acquiring an additional 3,198 shares in the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Key Headlines Impacting Charles River Laboratories International

Here are the key news stories impacting Charles River Laboratories International this week:

• Positive Sentiment: Q2 results exceeded expectations: Charles River reported adjusted earnings of $3.02 per share, above the $2.77 consensus estimate, while revenue of approximately $1.0 billion topped expectations of $977.2 million. The earnings beat came despite revenue declining 2.7% year over year. Charles River Q2 earnings report
• Positive Sentiment: Full-year guidance was raised: Management now expects fiscal 2026 adjusted EPS of $11.15-$11.45, above the $11.09 consensus estimate, and revenue of roughly $3.9 billion versus Wall Street expectations of $3.8 billion. The company also raised its free-cash-flow forecast to $400 million-$420 million. Charles River 2026 outlook
• Positive Sentiment: Demand trends are improving: Charles River cited stronger biotech demand for its discovery and development services. Analysts highlighted improving organic revenue and order trends, strong backlog and book-to-bill performance in the Discovery and Safety Assessment segment, and anticipated margin benefits from divestitures and cost reductions. Charles River lifts profit forecast
• Positive Sentiment: JPMorgan upgraded CRL: JPMorgan moved its rating from “neutral” to “overweight” and raised its price target to $310 from $180, signaling greater confidence in the company’s recovery and earnings trajectory.
• Neutral Sentiment: Executive stock sale: EVP Shannon M. Parisotto sold 5,046 shares for approximately $1.33 million under a pre-arranged Rule 10b5-1 trading plan. Although the sale reduced her direct holdings by more than half, the planned nature of the transaction makes it a limited near-term signal about management’s outlook. SEC insider transaction filing
• Negative Sentiment: Underlying risks remain: Quarterly EPS fell from $3.12 a year earlier, revenue declined year over year, and the Resources Management Services segment continues to face weakness in the U.S. These issues could limit the durability of the rally if demand improvement slows.

Analyst Ratings Changes

Several research firms recently issued reports on CRL. Royal Bank Of Canada upped their target price on Charles River Laboratories International from $215.00 to $282.00 and gave the company an “outperform” rating in a research report on Thursday. Evercore reiterated an “outperform” rating on shares of Charles River Laboratories International in a research note on Wednesday. Weiss Ratings upgraded Charles River Laboratories International from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 1st. Robert W. Baird set a $291.00 target price on Charles River Laboratories International in a report on Thursday. Finally, JPMorgan Chase & Co. upgraded Charles River Laboratories International from a “neutral” rating to an “overweight” rating and upped their target price for the company from $180.00 to $310.00 in a research report on Thursday. Twelve analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Charles River Laboratories International presently has an average rating of “Moderate Buy” and an average target price of $244.19.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.